Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Pfizer shares were lower on Tuesday despite third-quarter financial results that came in ahead of expectations. Sales of a ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

Pfizer › A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Metsera stock was tumbling on Monday after Pfizer agreed to buy the weight-loss drug start-up in a deal that could end up ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.

Pfizer (NYSE:PFE) stock rose 0.6% after the U.S. pharma giant clinched a $10 billion deal for obesity drug developer Metsera, ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

Investing.com - U.S. stock futures rose sharply Monday after the Senate voted in favor of a bill aimed at ending the ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors ...

A few years ago, Pfizer (NYSE: PFE) represented the ideal pharmaceutical stock investment. The company, as leader in the coronavirus vaccine and treatment market, offered a great deal of growth, and ...